1. Home
  2. BOLD vs INTS Comparison

BOLD vs INTS Comparison

Compare BOLD & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • INTS
  • Stock Information
  • Founded
  • BOLD 2018
  • INTS 2012
  • Country
  • BOLD United States
  • INTS United States
  • Employees
  • BOLD N/A
  • INTS N/A
  • Industry
  • BOLD
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOLD
  • INTS Health Care
  • Exchange
  • BOLD Nasdaq
  • INTS Nasdaq
  • Market Cap
  • BOLD 30.3M
  • INTS 30.8M
  • IPO Year
  • BOLD 2024
  • INTS 2023
  • Fundamental
  • Price
  • BOLD $1.42
  • INTS $1.85
  • Analyst Decision
  • BOLD Buy
  • INTS Strong Buy
  • Analyst Count
  • BOLD 3
  • INTS 3
  • Target Price
  • BOLD $22.50
  • INTS $8.50
  • AVG Volume (30 Days)
  • BOLD 69.6K
  • INTS 15.7K
  • Earning Date
  • BOLD 05-12-2025
  • INTS 05-08-2025
  • Dividend Yield
  • BOLD N/A
  • INTS N/A
  • EPS Growth
  • BOLD N/A
  • INTS N/A
  • EPS
  • BOLD N/A
  • INTS N/A
  • Revenue
  • BOLD N/A
  • INTS N/A
  • Revenue This Year
  • BOLD N/A
  • INTS N/A
  • Revenue Next Year
  • BOLD N/A
  • INTS N/A
  • P/E Ratio
  • BOLD N/A
  • INTS N/A
  • Revenue Growth
  • BOLD N/A
  • INTS N/A
  • 52 Week Low
  • BOLD $1.06
  • INTS $1.50
  • 52 Week High
  • BOLD $12.65
  • INTS $5.28
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • INTS 38.40
  • Support Level
  • BOLD N/A
  • INTS $1.78
  • Resistance Level
  • BOLD N/A
  • INTS $2.00
  • Average True Range (ATR)
  • BOLD 0.00
  • INTS 0.14
  • MACD
  • BOLD 0.00
  • INTS -0.00
  • Stochastic Oscillator
  • BOLD 0.00
  • INTS 24.22

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: